PCVXVaxcyte, Inc.

HealthcareUSD
$61.07

The financials

Vaxcyte, Inc. by the numbers

Vaxcyte, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$303M−$226Mn/a
Net income−$284M−$167Mn/a
Diluted EPS−$1.97−$1.22n/a

Biotechnology

Ranks #131 of 145 by Smart Score

Compare peers
SYRE+2.8%
Spyre Therapeutics, Inc.
IMVT+0.05%
Immunovant, Inc.
PTGX+0.39%
Protagonist Therapeutics, Inc.
RYTM+0.66%
Rhythm Pharmaceuticals, Inc.
IBRX-0.13%
ImmunityBio, Inc.
ABVX-0.15%
ABIVAX Société Anonyme